Get the Stockscreener App
1.64
3.53%
-0.06
Eledon Pharmaceuticals Inc stock is traded at $1.64, with a volume of 895.05K.
It is down -3.53% in the last 24 hours and down -13.23% over the past month.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and patients living with ALS. The company's compound in development is tegoprubart, an IgG1, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
See More
Previous Close:
$1.70
Open:
$1.7
24h Volume:
895.05K
Relative Volume:
0.42
Market Cap:
$123.06M
Revenue:
-
Net Income/Loss:
$-40.33M
P/E Ratio:
-0.9162
EPS:
-1.79
Net Cash Flow:
$-39.53M
1W Performance:
+3.80%
1M Performance:
-13.23%
6M Performance:
-45.33%
1Y Performance:
-62.73%
1-Day Range:
$1.64
$1.73
1-Week Range:
$1.56
$1.755
52-Week Range:
$1.35
$4.98
Eledon Pharmaceuticals Inc Stock (ELDN) Company Profile
Name
Eledon Pharmaceuticals Inc
Sector
Industry
Phone
949-238-8090
Address
19800 MACARTHUR BLVD., IRVINE
Compare ELDN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELDN
Eledon Pharmaceuticals Inc
|
1.64 | 127.56M | 0 | -40.33M | -39.53M | -1.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Eledon Pharmaceuticals Inc Stock (ELDN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-18-25 | Resumed | H.C. Wainwright | Buy |
| Jan-28-25 | Initiated | Guggenheim | Buy |
| May-13-22 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-23-21 | Initiated | Cantor Fitzgerald | Overweight |
Eledon Pharmaceuticals Inc Stock (ELDN) Latest News
Midday Stock Roundup: Rivian Rises on Chip, Models - Orange County Business Journal
Kidney Transplant Rejection Market on Track for Major Expansion by 2034, According to DelveInsight | GE Healthcare, Viela Bio, Eledon Pharma, Neovii Biotech, GlaxoSmithKline, Novartis, Medeor - Barchart.com
Kidney Transplant Rejection Market on Track for Major Expansion - openPR.com
Eledon Pharmaceuticals Inc Stock Analysis and ForecastPrice-to-Earnings Ratio Insights & Free Stock Index Interpretations - earlytimes.in
Why Eledon Pharmaceuticals Inc. stock is favored by pension fundsQuarterly Portfolio Review & Daily Profit Focused Screening - Newser
How analysts revise price targets for Eledon Pharmaceuticals Inc. (2TK) stockRisk Management & High Conviction Trade Alerts - Newser
Published on: 2025-12-04 05:40:36 - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock could be top winnerJuly 2025 Movers & Daily Risk Controlled Trade Plans - Newser
Is Eledon Pharmaceuticals Inc. (2TK) stock attractive post correctionBond Market & Verified High Yield Trade Plans - Newser
Why Eledon Pharmaceuticals Inc. (2TK) stock stays on buy lists2025 Dividend Review & Fast Momentum Stock Entry Tips - Newser
Eledon Pharmaceuticals (ELDN) Stock Analysis Report | Financials & Insights - Benzinga
Eledon Pharmaceuticals to Participate in the 37th Annual Piper Sandler Healthcare Conference - The Manila Times
What drives Eledon Pharmaceuticals Inc stock priceInflation Impact on Stocks & Capital Growth Strategies - earlytimes.in
Midday Stock Roundup: Eledon Up 4.8% - Orange County Business Journal
FY2025 Earnings Forecast for ELDN Issued By Leerink Partnrs - MarketBeat
United StatesMintz Advises On Eledon Pharmaceuticals’ $50 Million Follow-on Offering - Mondaq
Eledon Shares Fall Nearly 50% After Phase 2 Results - Orange County Business Journal
What is Eledon Pharmaceuticals Inc (ELDN) Stock Return on Shareholders’ Capital? - setenews.com
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
How analysts rate Eledon Pharmaceuticals Inc. stock todayWeekly Risk Summary & Growth Focused Stock Pick Reports - newser.com
Eledon Pharmaceuticals Reports Q3 2025 Financial Results - MSN
Will Eledon Pharmaceuticals Inc. (2TK) stock test record highs in 20252025 Risk Factors & Long-Term Growth Portfolio Plans - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock supported by strong fundamentalsJuly 2025 Closing Moves & High Return Stock Watch Alerts - newser.com
Eledon Pharmaceuticals (ELDN) Price Target Decreased by 14.93% to 8.33 - MSN
What technical patterns form on Eledon Pharmaceuticals Inc. (2TK) stock chartsWeekly Gains Report & Accurate Entry/Exit Alerts - newser.com
Is Eledon Pharmaceuticals Inc. (2TK) stock worth buying before Fed actionTrend Reversal & Free Safe Capital Growth Stock Tips - newser.com
Eledon Pharmaceuticals Inc. stock momentum explainedEarnings Beat & Free Community Consensus Stock Picks - newser.com
Can Eledon Pharmaceuticals Inc. (2TK) stock sustain margin levelsJuly 2025 EndofMonth & Capital Protection Trading Alerts - newser.com
Eledon’s transplant rejection drug shows promise in Phase I/II diabetes trial - Clinical Trials Arena
Visual trend scoring systems applied to Eledon Pharmaceuticals Inc.Weekly Profit Recap & AI Driven Price Forecasts - newser.com
Eledon Pharmaceuticals stock rises after positive islet transplant data By Investing.com - Investing.com Australia
Eledon Pharmaceuticals (ELDN) Reports Promising Trial Results fo - GuruFocus
Market reaction to Eledon Pharmaceuticals Inc.’s recent newsTrade Signal Summary & Safe Capital Investment Plans - newser.com
Eledon Pharmaceuticals Inc Stock (ELDN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):